Ginkgo Bioworks (DNA) Stock Forecast & Price Target

$6.37 -0.94 (-12.86%)

(As of 11/15/2024 ET)

Ginkgo Bioworks - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 5 Analyst Ratings

Sell
3

Hold
1

Buy
1

Based on 5 Wall Street analysts who have issued ratings for Ginkgo Bioworks in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 5 analysts, 3 have given a sell rating, 1 has given a hold rating, and 1 has given a buy rating for DNA.

Consensus Price Target

$4.58
-28.18% Downside

According to the 5 analysts' twelve-month price targets for Ginkgo Bioworks, the average price target is $4.58. The highest price target for DNA is $10.00, while the lowest price target for DNA is $0.30. The average price target represents a forecasted downside of -28.18% from the current price of $6.37.

Get the Latest News and Ratings for DNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Ginkgo Bioworks and its competitors.

DNA Analyst Ratings Over Time

Type	Current Forecast 11/16/23 to 11/15/24	1 Month Ago 10/17/23 to 10/16/24	3 Months Ago 8/18/23 to 8/17/24	1 Year Ago 11/16/22 to 11/16/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)
Hold	1 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$4.58	$4.16	$1.40	$3.19
Forecasted Upside	-28.18% Downside	-49.76% Downside	N/A	N/A
Consensus Rating	Reduce	Reduce	Reduce	Hold

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

DNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ginkgo Bioworks Stock vs. The Competition

Type	Ginkgo Bioworks	Medical Companies	S&P 500
Consensus Rating Score	1.60	2.80	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	-28.18% Downside	28,527.22% Upside	9.92% Upside
News Sentiment Rating	Neutral News See Recent DNA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/20/2024	TD Cowen 4 of 5 stars		Boost Target	Buy ➝ Buy	$3.00 ➝ $10.00	+26.90%
8/23/2024	BTIG Research 2 of 5 stars	M. Massaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sell ➝ Sell	$0.20 ➝ $7.00	-17.84%
7/9/2024	The Goldman Sachs Group 2 of 5 stars		Lower Target	Sell ➝ Sell	$0.80 ➝ $0.30	-6.66%
5/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $1.00	+25.14%
5/10/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Larew Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
11/14/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$3.50 ➝ $2.50	+94.55%
11/28/2022	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$6.00	+226.09%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:32 AM ET.

DNA Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Ginkgo Bioworks is $4.58, with a high forecast of $10.00 and a low forecast of $0.30.
: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 3 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" DNA shares.
: According to analysts, Ginkgo Bioworks's stock has a predicted downside of -28.18% based on their 12-month stock forecasts.
: Ginkgo Bioworks has been rated by research analysts at BTIG Research, and TD Cowen in the past 90 days.
: Analysts like Ginkgo Bioworks less than other "medical" companies. The consensus rating for Ginkgo Bioworks is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

This page (NYSE:DNA) was last updated on 11/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Stock Forecast & Price Target